Ramezani Alireza, Entezari Morteza, Moradian Siamak, Kadkhodaei Shohreh, Tabatabaei Homa, Dehsarvi Babak, Fatehi Mohammad, Yaseri Mehdi
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Ophthalmic Vis Res. 2011 Apr;6(2):101-8.
To evaluate the therapeutic effect of intravitreal triamcinolone (IVT) injection for recent branch retinal vein occlusion (BRVO).
In a randomized controlled clinical trial, 30 phakic eyes with recent (less than 10 weeks' duration) BRVO were assigned to two groups. The treatment group (16 eyes) received 4 mg IVT and the control group (14 eyes) received subconjunctival sham injections. Changes in visual acuity (VA) were the main outcome measure.
VA and central macular thickness (CMT) changes were not significantly different between the study groups at any time point. Within group analysis showed significant VA improvement from baseline in the IVT group up to three months (P < 0.05); the amount of this change was -0.53 ± 0.46, -0.37 ± 0.50, -0.46 ± 0.50, and -0.29 ± 0.45 logMAR at 1, 2, 3, and 4 months, respectively. Corresponding VA improvements in the control group were -0.20 ± 0.37, -0.11 ± 0.46, -0.25 ± 0.58, and -0.05 ± 0.50 logMAR (all P values > 0.05). Significant reduction in CMT was noticed only in the treatment group (-172 ± 202 μm, P = 0.029) and at 4 months. Ocular hypertension occurred in 4 (25%) and 2 (14.3%) eyes in the IVT and control groups, respectively.
A single IVT injection had a non-significant beneficial effect on VA and CMT in acute BRVO as compared to the natural history of the condition. The 3-month deferred treatment protocol advocated by the Branch Vein Occlusion Study Group may be a safer option than IVT injection considering its potential side effects.
评估玻璃体内注射曲安奈德（IVT）治疗近期发生的视网膜分支静脉阻塞（BRVO）的疗效。
在一项随机对照临床试验中，将30只患有近期（病程少于10周）BRVO的有晶状体眼分为两组。治疗组（16只眼）接受4mg IVT注射，对照组（14只眼）接受结膜下假注射。主要观察指标为视力（VA）变化。
在任何时间点，研究组之间的VA和中心黄斑厚度（CMT）变化均无显著差异。组内分析显示，IVT组在3个月内VA较基线有显著改善（P<0.05）；在第1、2、3和4个月时，这种变化的幅度分别为-0.53±0.46、-0.37±0.50、-0.46±0.50和-0.29±0.45 logMAR。对照组相应的VA改善分别为-0.20±0.37、-0.11±0.46、-0.25±0.58和-0.05±0.50 logMAR（所有P值>0.05）。仅在治疗组中观察到CMT在4个月时有显著降低（-172±202μm，P=0.029）。IVT组和对照组分别有4只（25%）和2只（14.3%）眼发生高眼压。
与该疾病的自然病程相比，单次IVT注射对急性BRVO的VA和CMT有不显著的有益作用。考虑到其潜在的副作用，分支静脉阻塞研究组提倡的3个月延迟治疗方案可能比IVT注射更安全。
